Radiopharmaceutical company developing copper-based theranostics for cancer diagnosis and treatment.
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Series B NUCLIDIUM raised €84M Series B led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners and Neva SGR to advance its copper-based cancer theranostics into clinical trials. | $97.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.